Immunotherapy-Induced Acute Gastritis: First Case Report of Nivolumab Re-Challenge after Severe Immune-Mediated Inflammatory Response

Authors

  • Ari Raphael
  • Yoram Menachem
  • Eli Barazovski
  • Oren Shibolet
  • Ravit Geva

Abstract

Background: The use of Checkpoint Inhibitors (CPIs) exposes patients to CPI immune-related adverse events (irAEs) that affect a variety of body organs and systems. IrAEs of the upper gastrointestinal tract and gastritis are rare manifestations of CPI-related IrAEs, with only a few cases reported in the literature. Currently, there are no guidelines for the evaluation, treatment and re-challenge after CPI-mediated gastritis.

Case Presentation: A fifty-eight-year-old male patient with hepatocellular carcinoma developed a rare irAE of acute gastritis after treatment with nivolumab. The immunotherapy was withdrawn and corticosteroids were administered, leading to complete symptom resolution. Nivolumab was then reinstated with good anti-tumor response and without recurrence of gastritis.

Conclusion: In our experience, nivolumab re-challenge after immune related gastritis was safe and resulted in a continued good clinical response.

Downloads

Published

2022-03-09

How to Cite

Raphael, A., Menachem, Y., Barazovski, E., Shibolet, O., & Geva, R. (2022). Immunotherapy-Induced Acute Gastritis: First Case Report of Nivolumab Re-Challenge after Severe Immune-Mediated Inflammatory Response. Archives of Clinical and Medical Case Reports, 6(2), 182–188. Retrieved from https://fortunejournals.org/ojs/index.php/acmcr/article/view/22594

Issue

Vol. 6 No. 2 (2022): Volume 6, Issue 2

Section

Articles